Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy

Abstract

TOP2A gene alterations (amplifications or deletions) are associated with an increase in responsiveness to anthracycline-containing chemotherapy regimens relative to non-anthracycline regimens that is similar to that seen in patients with HER2 amplification.